Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

WALGREENS BOOTS ALLIANCE, INC.

(WBA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Theranos founder Holmes denies misleading Walgreens

11/23/2021 | 11:40am EST

SAN JOSE, Calif., Nov 23 (Reuters) - Theranos founder Elizabeth Holmes denied lying to Walgreens about her company's technology during her fraud trial on Tuesday, offering rationales for withholding key details about operations and internal reports.

Holmes took the stand for a third day to defend herself against fraud accusations related to Theranos, a blood testing startup that is now defunct. The company had touted technology that could run diagnostic tests faster and more accurately than traditional lab testing with a drop of blood from a finger prick.

Jurors in San Jose, California, heard from a prosecutor at the start of the trial that Holmes falsely promised miniaturized blood analyzers to cement a partnership with Walgreens, but then secretly used "the big, clunky third-party machines" to test samples from patients who came into its stores.

On Tuesday, Holmes told jurors that she had been following legal advice when she withheld Theranos' use of third-party analyzers from Walgreens, as the modifications used to run small samples were Theranos' trade secret.

"The big medical device companies like Siemens could easily reproduce what we had done," she said.

Once valued at $9 billion, Theranos collapsed after the Wall Street Journal published a series of articles starting in 2015 that suggested its devices were flawed and inaccurate.

Holmes' decision to testify is risky as it exposes her to a potentially tough cross-examination by prosecutors.

Throughout her testimony, Holmes, 37, has sought to show that she believed Theranos' technology was capable of delivering on her claims, showing jurors encouraging emails from Theranos' scientists discussing the potential for a small machine to run any kind of test, and progress on developing it.

Holmes on Tuesday also denied misrepresenting Theranos' work with pharmaceutical companies Pfizer Inc and Schering-Plough by adding the companies' logos, which prosecutors have called an attempt to pass off Theranos' conclusions as theirs.

She admitted that she added the logos to the reports just before sending them to pharmacy operator Walgreens, which was discussing a partnership with Theranos in 2010, to convey the drugmakers' involvement in promising studies using Theranos technology.

"I wish I had done it differently," Holmes said.

Holmes also testified that she did not conceal the addition from Pfizer, showing jurors an email where the report with the logo was sent to individuals at Pfizer in 2014.

Over the two-month trial, jurors have heard testimony from more than two dozen prosecution witnesses, including patients and investors whom prosecutors say Holmes deceived.

Holmes has pleaded not guilty to nine wire fraud counts and two conspiracy counts.

Holmes is scheduled to resume testifying on Monday.

(Reporting by Jody Godoy in San Jose, Calif.; Editing by Matthew Lewis and Christopher Cushing)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
S&P 500 0.08% 4662.85 Delayed Quote.-2.17%
WALGREENS BOOTS ALLIANCE, INC. 0.20% 54.3 Delayed Quote.4.10%
All news about WALGREENS BOOTS ALLIANCE, INC.
01/14Walgreens, CVS shut some stores as Omicron variant complicates staffing issues
RE
01/14NORTH AMERICAN MORNING BRIEFING : Stock Futures Muted Ahead of Bank Earnings
DJ
01/13Tesco's operating cost inflation running at 5% - finance chief
RE
01/12MARKETSCREENER’S WORLD PRESS REVIEW : January 12, 2022
01/12Us private equity in for boots
AQ
01/11Walgreens, CVS cut paid sick leave for workers in line with CDC guidance
RE
01/11Walgreens starts strategic review for UK-based Boots business
RE
01/11Walgreens Boots Alliance Confirms Exploring Strategic Options for Boots
CI
01/11Walgreens CEO Says Company Has Begun Strategic Review of Boots Business
MT
01/11CVS lifts 2021 profit view on higher demand for COVID-19 vaccinations, tests
RE
More news
Analyst Recommendations on WALGREENS BOOTS ALLIANCE, INC.
More recommendations
Financials (USD)
Sales 2022 131 B - -
Net income 2022 5 740 M - -
Net Debt 2022 9 584 M - -
P/E ratio 2022 8,26x
Yield 2022 3,55%
Capitalization 46 876 M 46 876 M -
EV / Sales 2022 0,43x
EV / Sales 2023 0,39x
Nbr of Employees 258 500
Free-Float -
Chart WALGREENS BOOTS ALLIANCE, INC.
Duration : Period :
Walgreens Boots Alliance, Inc. Technical Analysis Chart | WBA | US9314271084 | MarketScreener
Technical analysis trends WALGREENS BOOTS ALLIANCE, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Last Close Price 54,30 $
Average target price 54,36 $
Spread / Average Target 0,10%
EPS Revisions
Managers and Directors
Rosalind Gates Brewer Chief Executive Officer & Director
John Standley President & Executive Vice President
James Kehoe Global Chief Financial Officer & Executive VP
Stefano Pessina Executive Chairman
Francesco Tinto Global Chief Information Officer & Senior VP